The University of Toronto and University of Vienna pharmacologist developed L-dopa, a precursor to dopamine that remains the most widely used therapy for Parkinson’s disease.

A novel preparation technique could facilitate vaccine preservation, transportation, and administration.

Wakelam, who died of a suspected COVID-19 infection, is remembered for his research on the physiological function of lipids.

A study in mice suggests serotonin release underlies the drug’s prosocial effects while dopamine mediates the rewarding properties that drive its potential for abuse.

A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.

An injectable biomaterial calls cancer drugs to tumor sites in mice.

The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.

The monoclonal antibody, known as mAb114, is likely to be used in the current Ebola outbreak in DRC.

Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.

Researchers use several different strategies to deliver a one-two punch.

The Scientist speaks with a clinical toxicologist to discuss how the supplement acts in the brain and what the agency's declaration means for research.

The University of Rhode Island neurotoxicologist and dean came to the U.S. for college in the 1980s. 

Scientists still don’t know exactly how some commonly used drugs work. Here’s a look at three such compounds.

Scientists discover compounds that restore antibiotic efficacy against drug-resistant superbugs.  

For decades, the only remedies for hearing loss were devices such as hearing aids or cochlear implants. Now, the first pharmaceutical treatments may be on the way.
 

Scientists create a photosensitive pharmaceutical to target a glutamate receptor.